甘露聚糖肽联合吡柔比星膀胱灌注预防膀胱癌术后复发的疗效观察Δ.pdfVIP

·基本药物应用· 甘露聚糖肽联合吡柔比星膀胱灌注预防膀胱癌术后复发的疗效观察Δ ＊ # 王 翔 ，刘 征，丁克家 ，曹庆伟（山东大学附属省立医院泌尿外科，济南 250000） 中图分类号 R737.14 文献标志码 A 文章编号 1001-0408（2013）24-2229-04 DOI 10.6039/j.issn. 1001-0408.2013.24.06 摘 要 目的：观察甘露聚糖肽联合吡柔比星膀胱灌注预防膀胱癌术后复发的临床疗效和安全性。方法：将78例非肌层浸润性 膀胱癌术后患者随机均分为治疗组和对照组，对照组采用吡柔比星30mg 膀胱灌注；治疗组采用40mg 甘露聚糖肽联合吡柔比星 30mg 膀胱灌注。两组均每周灌注1次，共8次，后每月灌注1次，共8次。定期复查膀胱镜，观察两组患者的复发率和不良反应。 结果：78例患者均获随访。治疗组患者复发率为5.13％，显著低于对照组的20.51％（P ＜0.05）。治疗组患者类似流感症状的发生 率显著高于对照组（P ＜0.05），而两组间其他不良反应的发生率比较差异无统计学意义（P ＞0.05）。结论：甘露聚糖肽联合吡柔比 星膀胱灌注能有效降低非肌层浸润性膀胱癌术后复发率，改善患者生存质量，且安全性较高，临床使用耐受性良好。 关键词 膀胱癌；术后复发；甘露聚糖肽；吡柔比星；膀胱；灌注；疗效；安全性 Efficacy Observation of Mannatide Combined with Pirarubicin by Bladder Instillation on Postoperative Re- currence of Bladder Cancer WANG Xiang ，LIU Zheng ，DING Ke-jia ，CAO Qing-wei （Dept. of Urology ，Provincial Hospital Affiliated to Shandong University ，Jinan 250000，China ） ABSTRACT OBJECTIVE ：To observe clinical efficacy and safety of mannatide combined with pirarubicin by bladder instillation on postoperative recurrence of bladder cancer. METHODS ：A total of 78patients underwent non-muscle invasive bladder cancer sur- gery were randomized into treatment group and control group. Control group received only pirarubicin （30mg ）by bladder instilla- tion. Mannatide （40mg ）combined with pirarubicin （30mg ）was administered to treatment group. Both were given medicines once a week for 8 times ，then once a month for 8 times. Periodical cystoscopy was performed ，and the recurrent rate of bladder cancer and adverse drug reactions （ADR ）were observed. RESULTS ：A total of 78 cases obtained follow-up visit. The recurrent rate of bladder cancer in treatment group was 5.13％，which was significantly lower than 20.51％in control group （P ＜0.05）；the inci- dence rate of flu-like symptoms in treatment group was higher than in control g